23 completed, 10 unknown, 8 terminated, 5 recruiting. 53 Phase 1, 24 Phase 2.
Follow Burns: new trials by email Literature Review of Burns trials Research Report on Burns
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Magnesium Sulfate in Pediatric Burn Dressing Changes magnesium sulfate, Normal Saline (0.9% NaCl) - Pediatric Burns | Phase 1 | Not yet recruiting | Hennepin Healthcare Research Institute | 10 | 2027-12-01 | 2026-10-09 |
| HUMSCs Combined With Col I to Third-Degree Burn Wound HUMSCs combined with bovine type I collagen, bovine type I collagen, Sterile blank dressing / Vaseline gauze - Burn Wounds, Third-Degree Burn Wounds | Phase 1 / Phase 2 | Recruiting | The First Affiliated Hospital of Xinxiang Medical College | 108 | 2026-04-06 | 2026-05-04 |
| Use of Progenitor Biological Bandages in Burn Care (Bru_PBB) Progenitor Biological Bandages, Jelonet - Burn Injury | Phase 1 / Phase 2 | Terminated | Dr Anthony De Buys Roessingh | 76 | 2025-07-01 | 2025-07-22 |
| SN514-066b Enzyme in Deep Partial Thickness Burns SN514-066b - Burn Injury | Phase 1 / Phase 2 | Terminated | SERDA bv | 13 | 2025-05-08 | 2026-10-30 |
| A Study to Evaluate the Safety, Tolerability and Efficacy in Patients With Burn(s) PMS-101, Standard treatment - Burns, Burn Degree Second | Phase 1 / Phase 2 | Unknown | Primoris Therapeutics | 40 | 2025-01-01 | 2024-07-05 |
| Clinical Assessment of Protopic® Ointment in Deep Partial-Thickness Burns Tacrolimus ointment - Burn Injury | Phase 1 | Terminated | Vanderbilt University Medical Center | 1 | 2024-09-19 | 2026-07-29 |
| A Phase I, Single-blind, Randomized Study of the Safety and Efficacy of Cellularized Integra® Using Autologous Burn-derived Stem Cells Integra®, Integra®-SC - Burns | Phase 1 | Not yet recruiting | Hamilton Health Sciences Corporation | 29 | 2024-02-01 | 2023-12-15 |
| Phase 1 Healthy Volunteer Burn Therapy Study cNP8, Placebo - Burns | Phase 1 | Completed | Neomatrix Therapeutics, Inc. | 32 | 2024-01-30 | 2024-11-14 |
| Organ Protective Effect of Cetirizine In Patients With Severe Burns Cetirizine, Midazolam and Fentanyl - Burns | Phase 1 / Phase 2 | Unknown | Ruijin Hospital | 32 | 2024-01-23 | 2024-02-01 |
| Comparison Between Carbapenems and Noncarbapenem Beta-lactam Antibiotics in Septic Burn Patients Meropenem I.V. 2g as a 3 hour infusion every 8 hours, Tazocin (pipercillin/tazobactam) - Sepsis | Phase 1 / Phase 2 | Active not recruiting | Ain Shams University | 400 | 2024-01-01 | 2025-10-03 |
| Safety of Extracellular Vesicles for Burn Wounds AGLE-102 - Burns | Phase 1 | Completed | Aegle Therapeutics | 1 | 2023-08-10 | 2024-11-20 |
| Phage Therapy for the Prevention and Treatment of Wound Infections in Burned Patients Bacteriophage cocktail spray, Xeroform - Wound Infection | Phase 1 | Unknown | Precisio Biotix Therapeutics, Inc. | 12 | 2022-01-01 | 2021-12-22 |
| A Between Patient Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries PluroGel, Standard dressing - Burns | Phase 1 / Phase 2 | Recruiting | University of Manitoba | 25 | 2021-10-20 | 2026-05-14 |
| A Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries Standard dressing, PluroGel - Burns | Phase 1 / Phase 2 | Recruiting | University of Manitoba | 20 | 2021-10-01 | 2026-05-14 |
| MSCs for the Treatment of Burn Wounds Implantation of allogeneic MSCs on burn wounds - Burn Wound, Second- or Third-degree Burn | Phase 1 / Phase 2 | Unknown | Instituto Venezolano de Investigaciones Cientificas | 50 | 2021-06-30 | 2023-10-26 |
| CellMist™ Autologous Cells to Treat Deep Second-Degree Burns CellMist™ System - Burns, Burns Second Degree | Phase 1 | Unknown | RenovaCare, Inc | 14 | 2021-05-26 | 2022-03-15 |
| Evaluation of Safety and Efficacy of realSKIN® (Skin Xenotransplant) for Complete Closure of Severe Burn Wounds realSKIN (skin xenotransplant), Human Cadaver Allograft - Deep Full-thickness Burn Injury (Disorder) | Phase 1 / Phase 2 | Completed | XenoTherapeutics, Inc. | 25 | 2019-03-15 | 2024-01-12 |
| Wound Healing Endpoint and Recurrence Epiceram Skin Barrier Function, Vaseline Petroleum Jelly - Chronic Wound, Burn Wound | Phase 1 / Phase 2 | Active not recruiting | Sashwati Roy | 100 | 2019-01-08 | 2025-09-26 |
| Investigation of Thermal Injury on Intestinal Permeability in Both Thermal Injury and Healthy Participants Lactulose and Mannitol solution, Sucralose - Burns | Phase 1 | Terminated | GlaxoSmithKline | 18 | 2018-01-29 | 2019-08-19 |
| Treatment of Patients With Skin Burns Using Keratinocytes and Skin Fibroblasts Fibroblasts and keratinocytes - Burns | Phase 1 / Phase 2 | Completed | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | 12 | 2017-01-01 | 2020-07-24 |
Showing 20 of 53. Sign in to see all of them.
Wounds and Injuries (8) · Cicatrix (3) · Infections (3) · Anxiety Disorders (2) · Bacterial Infections (2) · Diabetic Foot (2) · Neoplasm Metastasis (2) · Sepsis (2) · Sunburn (2) · Wound Infection (2) · Agnosia (1) · Blood Loss, Surgical (1) · Bone Demineralization, Pathologic (1) · Bronchiolitis Obliterans Syndrome (1)
Wounds and Injuries (45) · Pathological Conditions, Signs and Symptoms (10) · Pathologic Processes (8) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Fibrosis (3) · Infections (3) · Neoplasms (3) · Nutritional and Metabolic Diseases (3) · Signs and Symptoms (3) · Bacterial Infections and Mycoses (2) · Cardiovascular Diseases (2) · Diabetes Complications (2) · Diabetes Mellitus (2)
2,4,6-tribromophenol (2) · Analgesics (1) · Anti-Bacterial Agents (1) · Ascorbic Acid (1) · Bacitracin (1) · Calcium (1) · Cetirizine (1) · Cholecalciferol (1) · Dexmedetomidine (1) · Doxycycline (1) · Ergocalciferols (1) · Fentanyl (1) · Fibrin Tissue Adhesive (1) · Gramicidin, Neomycin Sulfate, Nystatin, Triamcinolone Acetonide Drug Combination (1) · Lactulose (1)
University of Manitoba (3) · MetroHealth Medical Center (2) · Shriners Hospitals for Children (2) · Stratatech, a Mallinckrodt Company (2) · A.A. Partners, LLC (1) · Aegle Therapeutics (1) · Ain Shams University (1) · Anterogen Co., Ltd. (1) · Arteriocyte, Inc. (1) · Baxter Healthcare Corporation (1) · Biotec Pharmacon ASA (1) · CHU de Quebec-Universite Laval (1) · Centre Hospitalier Universitaire Vaudois (1) · Chulalongkorn University (1) · Critical Biologics Corporation (1)
United States (25) · Canada (6) · China (3) · Switzerland (3) · Egypt (2) · Australia (1) · Belarus (1) · Denmark (1) · France (1) · Hong Kong (1) · Israel (1) · Norway (1) · South Korea (1) · Ukraine (1) · United Kingdom (1)
Alexey Chasnoit, Dr (1) · Anatoliy V. Voronin (1) · Andrew L Blount, MD (1) · Anthony De Buys Roessingh (1) · Arnold Luterman, MD (1) · Aya A Bayoumy, MD (1) · Brian Barnes, PhD (1) · Carl Schulman, MD (1) · Carl Schulman, MD, PhD (1) · Cecilie Scheuer, Research Scholar (1) · Celeste C Finnerty, Ph.D. (1) · Charles J Yowler, MD, FACS (1) · Charles Yowler, MD (1) · Daniel L Traber, PhD (1)
PMID 11525858, PMID 11753055, PMID 12694482, PMID 12890465, PMID 15175591, PMID 15269581, PMID 17356164, PMID 17960651, PMID 19276766, PMID 21475006, PMID 28602587, PMID 33305842, PMID 34398099, PMID 35953455, PMID 36843581, PMID 39115183, PMID 40407357, PMID 8454661, PMID 9852660
R44AR047499 (1)